Apizaban-5

Mode of action

Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effect on inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis

Apixapan tablets 5mg

Class: Anticoagulant

Manufacturer: 4Care Lifescience Pvt. Ltd, Survey no. 23/3P & 24, Opp. Jeans Factory, Daduram vistar, Village bagdol, tal. – Kathlal, Dist. Khenda-387630, Gujarat, India

Dosage Form: Tablet

Similar Brands: Thromban Tablets

Uses:

Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

Prevention of stroke and systemic embolism in adult with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attach (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA class ≥ II).

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Dosage:

For oral administration

Adults

To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least on additional risk factor.

The recommended dose is on tablet of apixaban 5mg twice a day

To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs

The recommended dose is two tablets of apixaban 5mg twice a day for the first 7 days, for example, two in the morning and two in the evening.

After 7 days the recommended dose is one tablet of apixaban 5mg twice a day, for example on in the morning and one in the evening.

Side Effects:

  • Bleeding, including; from nose, from gums, blood in urine, bruising and swelling, from stomach, bowel and rectum
  • Anemia which may cause tiredness or paleness
  • Reduced number of platelets in blood.
  • Nausea
  • Skin rash

Warnings & Precautions:

Haemorrhage risk; as with other anticoagulants, patients taking apixaban are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage.

Interaction with other medical products affecting haemostasis: Care is to be taken if patients are treated concomitantly with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or non-steroidal anti-inflammatory medicinal products (NSAIDs), including acetylsalicylic acid.

Patients with antiphospholipid syndrome: Direct acting oral anticoagulants (DOACs) including apixaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome.

Patients with renal impairment; Limited clinical data indicate that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15-29mL/min) which may lead to an increased bleeding risk.

Patients with hepatic impairment; Apixaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk.

Pregnancy & Lactation:

Pregnancy

As a precautionary measure, it is preferable to avoid the use of apixaban during preagnancy.

Breast feeding

It is unknown whether apixaban or its metabolites are excreted in human milk. Like other drugs apixaban should only be used during breast-feeding if considered essential.

Drug Interactions:

SSRIs, NSAIDs, oral anticoagulants

Contraindications:

  • Hypersensitivity to the active substance.
  • Active clinically significant bleeding.
  • Hepatic disease associated with coagulopathy and clinically relevant risk.
  • Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
  • Concomitant treatment with any other anticoagulant agent e.g. unfractioned heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc), heparin derivatives (fondoparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy, when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation.

Price: Ksh 1,350

Notes:

Pack size: 30s

Marketed by:

Avetina Lifesciences Ltd.

P.O BOX: 3328-00506, Nairobi Kenya

Email Id: info@avetinalife.com

Website: www.avetinalife.com